These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 4817094)

  • 21. [Therapy of immuninhibitor hemophilia A with FEIBA plasma fraction].
    István L; Bariska I; Marton E
    Orv Hetil; 1980 Dec; 121(51):3131-5. PubMed ID: 6784062
    [No Abstract]   [Full Text] [Related]  

  • 22. [Prophylaxis in hemophilia].
    Ortega F; Martin-Villar J; Navarro JL
    Sangre (Barc); 1970; 15(3):355-61. PubMed ID: 5486763
    [No Abstract]   [Full Text] [Related]  

  • 23. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
    Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of porcine factor VIII in France.
    Negrier C
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):29-32. PubMed ID: 7939770
    [No Abstract]   [Full Text] [Related]  

  • 25. Hemophilia with factor VIII inhibitor. Elimination of anamnestic response.
    Stein RS; Colman RW
    Ann Intern Med; 1973 Jul; 79(1):84-7. PubMed ID: 4124485
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of frequent factor VIII replacement on the level of factor VIII antibodies in haemophiliacs.
    Rizza CR; Matthews JM
    Br J Haematol; 1982 Sep; 52(1):13-24. PubMed ID: 6810911
    [No Abstract]   [Full Text] [Related]  

  • 27. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A].
    Ferencz T; Skopál J; Csáki C; Laczkó M; Schuler D; Borsi J
    Orv Hetil; 1993 Dec; 134(52):2873-5. PubMed ID: 8272354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired hemophilia and its treatment.
    Sultan Y
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S15-8. PubMed ID: 9351531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment and outcome of acquired haemophilia A with a standard conventional regimen in a cohort without associated conditions.
    Ng HJ; Tan DC; Lee LH
    Haemophilia; 2006 Jul; 12(4):423-8. PubMed ID: 16834745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Side-effects of factor VIII substitution in patients with hemophilia A (author's transl)].
    Tilsner V; Reuter H
    MMW Munch Med Wochenschr; 1982 Jun; 124(22):553-7. PubMed ID: 6808385
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of cryoprecipitate antihaemophilic factor for the treatment of haemophilia.
    Bloom AL; Emmanuel JH
    Q J Med; 1968 Apr; 37(146):291-302. PubMed ID: 5656159
    [No Abstract]   [Full Text] [Related]  

  • 33. Acquired circulating anticoagulants in hemophilia A.
    Strauss HS
    N Engl J Med; 1969 Oct; 281(16):866-73. PubMed ID: 5812255
    [No Abstract]   [Full Text] [Related]  

  • 34. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune tolerance induction and the treatment of hemophilia. Malmö protocol update.
    Berntorp E; Astermark J; Carlborg E
    Haematologica; 2000 Oct; 85(10 Suppl):48-50; discussion 50-1. PubMed ID: 11187871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Very-high-purity versus intermediate-purity factor VIII in human immunodeficiency virus-positive hemophiliacs: conclusions of a prospective 3-year study. Monoclate Study Group.
    Seremetis SV
    Semin Hematol; 1993 Oct; 30(4 Suppl 5):10-3. PubMed ID: 7903480
    [No Abstract]   [Full Text] [Related]  

  • 37. [Factor VIII inhibitor-caused hemophilia].
    Peto I; Bánhegyi D; Nemesánszky E; Köves A; Sas G
    Orv Hetil; 1977 Sep; 118(36):2145-9. PubMed ID: 917507
    [No Abstract]   [Full Text] [Related]  

  • 38. [Combined treatment with factor VIII and immunosuppressive agents in a young woman with acquired factor VIII inhibitor].
    José Aguado M; Carrasco V; Periago A; Bello T; González E; García-Talavera J
    Sangre (Barc); 1996 Apr; 41(2):147-50. PubMed ID: 9045356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A guide for home treatment--Madrid 1978.
    Scand J Haematol Suppl; 1980; 35():1-27. PubMed ID: 6770457
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.